Methods for treating congestive heart failure
View Patent ↗The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene.
1. A method for treating or preventing congestive heart failure in a mammal, said method comprising administering a polypeptide comprising an epidermal growth factor-like (EGF-like) domain to said mammal,
wherein said EGF-like domain is encoded by a neuregulin gene selected from the group consisting of an NRG-1 gene, an NRG-2 gene, and an NRG-3 gene, and
wherein said administering is in an amount effective to treat or prevent heart failure in said mammal.
2. The method of claim 1 , wherein said mammal is a human.
3. The method of claim 1 , wherein said congestive heart failure results from hypertension; ischemic heart disease; exposure to a cardiotoxic compound; myocarditis; thyroid disease; viral infection; gingivitis; drug abuse; alcohol abuse; periocarditis; atherosclerosis; vascular disease; hypertrophic cardiomyopathy; acute myocardial infarction; left ventricular systolic dysfunction; coronary bypass surgery; starvation; an eating disorder; or a genetic defect.
4. The method of claim 3 , wherein said mammal has undergone a myocardial infarction.
5. The method of claim 3 , wherein said cardiotoxic compound is an anthracycline; alcohol; or cocaine.
6. The method of claim 5 , wherein said anthracyline is doxorubicin, or daunomycin.
7. The method of claim 6 , wherein an anti-ErbB2 or anti-HER2 antibody is administered to said mammal before, during, or after anthracycline administration.
8. The method of claim 3 , wherein said cardiotoxic compound is an anti-ErbB2 or anti-HER2 antibody.
9. The method of claim 7 or 8 , wherein said anti-ErbB2 or anti-HER2 antibody is trastuzumab.
10. The method of claim 3 , wherein said polypeptide is administered prior to exposure to said cardiotoxic compound.
11. The method of claim 3 , wherein said polypeptide is administered during exposure to said cardiotoxic compound.
12. The method of claim 3 , wherein said polypeptide is administered after exposure to said cardiotoxic compound.
13. The method of claim 1 , wherein said polypeptide is administered prior to the diagnosis of congestive heart failure in said mammal.
14. The method of claim 1 , wherein said polypeptide is administered after the diagnosis of congestive heart failure in said mammal.
15. The method of claim 1 , wherein said polypeptide is administered to a mammal that has undergone compensatory cardiac hypertrophy.
16. The method of claim 1 , wherein administration of said polypeptide maintains left ventricular hypertrophy.
17. The method of claim 1 , wherein said method prevents progression of myocardial thinning.
18. The method of claim 1 , wherein administration of said polypeptide inhibits cardiomyocyte apoptosis.
19. The method of claim 1 , wherein said polypeptide is administered by administering an expression vector encoding said polypeptide to said mammal.
20. The method of claim 1 , wherein the mammal is at risk for congestive heart failure.
21. The method of claim 20 , wherein the mammal is an individual that smokes, is obese, has been or will be exposed to a cardiotoxic compound, has or had high blood pressure, has or had ischemic heart disease, has or had a myocardial infarct, has a genetic defect that increases the risk of heart failure, has a family history of heart failure, has or had myocardial hypertrophy, has or had hypertrophic cardiomyopathy, has or had left ventricular systolic dysfunction, had coronary bypass surgery, has or had vascular disease, has or had atherosclerosis, has or had alcoholism, has or had pericarditis, has or had a viral infection, has or had gingivitis, has or had an eating disorder, has or had myocarditis, has or had a thyroid disease, or is a cocaine addict.
22. The method of claim 1 , wherein the mammal has or had a cancer.
23. The method of claim 22 , wherein the cancer is breast cancer.
24. The method of claim 1 , wherein the polypeptide is administered by a parenteral, intravenous, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intracisternal, intraperitoneal, intranasal, aerosol, oral, or topical route.
25. The method of claim 1 , wherein the polypeptide comprises recombinant human GGF2, and wherein the polypeptide is administered at a dose of 0.3 mg/kg.